Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Classifica tra le azioni #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Prezzo delle azioni
$62.49
Ultima sincronizzazione: 2024-03-06
Capitalizzazione di mercato
$2.52B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia RayzeBio, Inc. Common Stock (RYZB)

Categoria

Storico del prezzo dell'azione per RayzeBio, Inc. Common Stock (RYZB)
Prezzo di chiusura più alto: $62.49 il 2024-03-01

Prezzo di chiusura più basso: $20.99 il 2023-09-01
Storico del prezzo dell'azione di RayzeBio, Inc. Common Stock dal 2023 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 87.31%
2023 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$549.38 41.20%
US
$1.05K 47.75%
NL
$148.35 491.02%
US
$122.63 -12.65%
AU
$763.17 6.90%
CH